LFQ (label-free quantification) and iBAQ (intensity-based absolute quantification) are both intensity-derived readouts commonly computed from unlabeled data-dependent acquisition (DDA) proteomics data, yet they answer different quantitative questions. LFQ compares the same protein across independently acquired samples after cross-run alignment and normalization. iBAQ ranks relative molar abundance among different proteins within one sample by dividing summed peptide intensities by the number of theoretically observable peptides. Neither value is a calibrated protein concentration from a matched isotope standard. Choose LFQ when the claim is differential change between groups; choose iBAQ when the claim is abundance composition inside a proteome; report both only when those two claims are both needed.

Researchers who already have defined samples, comparison groups, or a specific project objective can also review the MtoZ Biolabs Label-Free Quantitative Proteomics Service for project-specific feasibility and analysis planning.

How LFQ and iBAQ Differ in What They Compare

The practical difference is the comparison axis. LFQ asks whether protein A changes from sample 1 to sample 2. iBAQ asks whether protein A appears more abundant than protein B inside the same run or sample after length-aware intensity scaling (Schwanhausser et al. 2011). Confusing those axes produces the wrong statistical test and the wrong biological sentence.

Both metrics often appear in the same MaxQuant-style protein table from one DDA search. Shared origin does not make them interchangeable. An LFQ intensity supports a between-sample contrast for one protein group. An iBAQ value supports a within-sample ranking across protein groups. Using iBAQ fold changes between conditions without checking how missingness and identification depth differ across runs can reintroduce the very run-to-run issues that LFQ algorithms were designed to control.

Figure 1. LFQ compares the same protein across independently acquired samples; iBAQ ranks different proteins inside one sample after intensity is scaled by theoretical peptide count.

LFQ and iBAQ can share one unlabeled DDA dataset; they do not share the same quantitative claim.

What LFQ Measures Across Samples

LFQ is a relative, label-free strategy. Each digest is injected as its own liquid chromatography-tandem mass spectrometry (LC-MS/MS) run. Peptide identities come from fragment spectra searched against a protein database. Quantitative values usually come from MS1 chromatographic peak areas of identified peptides after features are matched across runs (Cox et al. 2014). Protein-level LFQ intensities summarize those peptide signals so that the same protein can be compared across the declared groups.

The working assumption is narrow. Under comparable chromatography and instrument response, more precursor signal for a given peptide supports a higher relative amount of that same peptide. The assumption does not say that two different peptides with similar intensity represent similar molar amounts, because digestion, ionization, and interference differ by sequence.

Design conditions that favor LFQ

LFQ fits studies that need relative discovery without isotopic or chemical labeling: treatment versus control, genotype panels, time courses, and clinical cohorts that arrive over a planned acquisition window. It is often preferred when multiplex channel count, labeling chemistry, or sample chemistry would constrain the set. Independence of each injection is also the main cost. Loading, retention-time drift, and batch structure must be controlled by design, alignment, and normalization before differential testing.

Limits that belong in the LFQ methods record

Missing values are expected, especially at low abundance. Match-between-runs can reduce missingness and can transfer incorrect assignments if tolerances are too open. Shared peptides, unique-peptide filters, and protein-inference rules change which rows enter the matrix. LFQ intensities remain relative. They do not report copies per cell or a tissue concentration.

Researchers who need a fuller definition of unlabeled discovery boundaries can refer to What Is Label-Free Quantification in Proteomics? for workflow and interpretation limits beyond the LFQ versus iBAQ contrast.

Figure 2. LFQ depends on stable independent runs and cross-run alignment; the valid readout is same-protein relative change, not cross-protein molar ranking.

What iBAQ Estimates Within One Sample

iBAQ estimates relative protein abundance within a sample by summing intensities of peptides identified for a protein and dividing by the number of theoretically observable peptides for that sequence, commonly after tryptic rules (Schwanhausser et al. 2011). The division corrects, in part, for protein length: longer proteins tend to yield more peptides and would otherwise accumulate more total intensity for the same molar amount.

The output is a within-sample abundance proxy that can support proteome composition statements, such as whether structural proteins dominate enzymatic ones in a profile, or how protein classes contribute to total intensity after length scaling. iBAQ is often described as closer to absolute quantification than raw intensity because it aims at relative molar ranking. It is still an intensity surrogate. Without a matched standard and calibration model, it is not a certified copy-number assay, and published absolute scaling of iBAQ-derived copy numbers requires additional assumptions that must be stated.

iBAQ quality tracks identification completeness. Proteins with few observed peptides inherit higher uncertainty. Contaminants, reverse hits, and only-identified-by-site entries should be filtered before compositional interpretation. Comparing iBAQ values across distant experiments without shared processing and reporting rules overstates reproducibility.

Side-by-Side Differences That Affect Interpretation

Dimension	LFQ	iBAQ
Primary question	Same protein across samples or groups	Different proteins inside one sample
Typical signal base	Matched MS1 peak areas after alignment and normalization	Summed peptide intensities scaled by theoretical peptide count
Output interpretation	Relative abundance change (often used with fold change and statistics)	Relative molar ranking or composition proxy
Labeling requirement	None	None
Main vulnerability	Run-to-run chromatography and missingness	Incomplete peptide coverage and length-model assumptions
Not suitable for	Ranking different proteins by molar amount from LFQ intensity alone	Calibrated absolute concentration without standards

These rows describe common DDA label-free practice. Software implementations differ in peptide selection, intensity extraction, and theoretical-peptide rules. The methods section should name the algorithm version and the filters applied to both metrics.

When to Choose LFQ, iBAQ, or Both

Prefer LFQ when the study contrast is differential expression across predefined groups and the scientific sentence will cite fold change, adjusted significance, and replicate consistency for the same protein. Prefer iBAQ when the study needs an abundance composition view inside a sample or a length-aware ranking across the measured proteome.

Both can be reported from one unlabeled project when the manuscript needs a between-group differential table and a within-sample composition summary. They should not be mixed in one test without stating which metric entered the model. iBAQ ratios between conditions are not automatically more accurate than LFQ contrasts; they answer a different question and inherit different missing-value behavior.

Figure 3. Selection follows the claim: LFQ for differential change of the same protein across groups; iBAQ for abundance composition among proteins inside one sample.

If the claim needs a calibrated amount, plan a targeted assay with standards rather than renaming LFQ or iBAQ as absolute quantification.

LFQ Application Boundaries in Common Study Types

Label-free LFQ is frequently used for cell-treatment screens, tissue-state comparisons, and clinical cohort discovery when labeling is impractical. Those applications still require declared groups, controlled injection order, and a normalization plan before volcano plots are interpreted. Pathway enrichment on LFQ candidates reflects overrepresentation in a submitted list relative to a quantified background. It does not prove pathway activity.

iBAQ-based composition profiles are useful for estimating how much of the measured proteome is carried by major protein classes, or for feeding systems models that need relative molar inputs. They remain model inputs, not validated cellular copy numbers, unless the absolute scaling method is separately validated.

When sample chemistry, cohort size, or later enrollment make labeling versus unlabeled discovery less straightforward, the LFQ versus iBAQ choice is still secondary to whether an unlabeled independent-injection design fits the project at all.

Frequently Asked Questions

1. Are LFQ and iBAQ two different laboratory experiments?

Not necessarily. Both are commonly computed from the same unlabeled DDA dataset. The difference is the quantitative question and the calculation, not a separate digestion chemistry.

2. Can iBAQ replace LFQ for differential expression?

Generally no. Differential claims across groups are usually built on LFQ or related cross-run relative intensities with alignment and normalization. iBAQ is built for within-sample relative molar ranking.

3. Is iBAQ true absolute quantification?

No. iBAQ provides a length-aware intensity proxy for relative molar abundance. Absolute concentration or copy-number claims need matched standards and a stated calibration model.

4. Can LFQ intensities rank protein A against protein B?

No. LFQ supports same-protein comparison across samples. Cross-protein molar ranking is outside the LFQ claim and is closer to the iBAQ question, still without calibrated absolute amounts.

5. Should every label-free project report both metrics?

Only when both claims are needed. Reporting both without stating which metric supports which figure creates ambiguous interpretation. Prefer one primary metric per scientific sentence.

Once the comparison axis, sample workflow, and expected protein-level output are defined, the project can be evaluated as a label-free quantitative study with an explicit LFQ, iBAQ, or dual-readout plan. Researchers can review the MtoZ Biolabs Label-Free Quantitative Proteomics Service for sample evaluation, feasibility assessment, and workflow planning.

Reference

1. J. Cox, M.Y. Hein, C.A. Luber, I. Paron, N. Nagaraj, M. Mann (2014). Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics, 13, 2513-2526. https://doi.org/10.1074/mcp.M113.031591
2. B. Schwanhausser, D. Busse, N. Li, G. Dittmar, J. Schuchhardt, J. Wolf, W. Chen, M. Selbach (2011). Global quantification of mammalian gene expression control. Nature, 473, 337-342. https://doi.org/10.1038/nature10098